CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.557
AS - Asia 9.500
EU - Europa 9.243
SA - Sud America 1.394
Continente sconosciuto - Info sul continente non disponibili 373
AF - Africa 268
OC - Oceania 34
Totale 46.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.175
SG - Singapore 2.834
GB - Regno Unito 2.660
CN - Cina 1.898
IT - Italia 1.699
HK - Hong Kong 1.287
VN - Vietnam 1.180
BR - Brasile 1.073
DE - Germania 826
FI - Finlandia 738
BD - Bangladesh 708
SE - Svezia 691
IE - Irlanda 441
UA - Ucraina 433
FR - Francia 402
RU - Federazione Russa 369
PL - Polonia 368
TR - Turchia 364
IN - India 254
CA - Canada 222
ID - Indonesia 200
BG - Bulgaria 190
JP - Giappone 115
IQ - Iraq 101
AR - Argentina 99
KR - Corea 93
MX - Messico 78
EG - Egitto 59
ES - Italia 59
NL - Olanda 57
EC - Ecuador 53
PK - Pakistan 53
ZA - Sudafrica 50
VE - Venezuela 48
MY - Malesia 47
BE - Belgio 44
LT - Lituania 43
AE - Emirati Arabi Uniti 40
MA - Marocco 40
CO - Colombia 36
PH - Filippine 36
AT - Austria 33
NP - Nepal 32
CL - Cile 31
TW - Taiwan 31
UZ - Uzbekistan 31
TN - Tunisia 26
AU - Australia 25
CZ - Repubblica Ceca 25
JO - Giordania 25
SA - Arabia Saudita 25
KE - Kenya 23
RO - Romania 22
CH - Svizzera 20
PY - Paraguay 20
DZ - Algeria 19
IR - Iran 18
EU - Europa 17
MD - Moldavia 16
TH - Thailandia 16
DO - Repubblica Dominicana 15
PT - Portogallo 15
AZ - Azerbaigian 14
HU - Ungheria 14
IL - Israele 13
PE - Perù 13
UY - Uruguay 13
CR - Costa Rica 11
NO - Norvegia 11
SN - Senegal 11
OM - Oman 10
JM - Giamaica 9
AL - Albania 8
HN - Honduras 8
KZ - Kazakistan 8
SY - Repubblica araba siriana 8
BH - Bahrain 7
ET - Etiopia 7
NZ - Nuova Zelanda 7
PA - Panama 7
RS - Serbia 7
BO - Bolivia 6
DK - Danimarca 6
GH - Ghana 6
HR - Croazia 6
LB - Libano 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
AO - Angola 5
CY - Cipro 5
GE - Georgia 5
GR - Grecia 5
GT - Guatemala 5
MT - Malta 5
PS - Palestinian Territory 5
SV - El Salvador 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CG - Congo 4
KG - Kirghizistan 4
Totale 45.934
Salva come PNG Salva come JPEG
Città #
Fairfield 3.220
Ashburn 2.566
Santa Clara 1.935
Singapore 1.809
Woodbridge 1.804
Southend 1.676
Houston 1.467
Seattle 1.268
Hong Kong 1.263
Chandler 1.184
Cambridge 1.023
Wilmington 1.012
Jacksonville 748
Dearborn 736
Ann Arbor 731
San Jose 691
Helsinki 599
Beijing 547
London 489
Nyköping 468
Council Bluffs 441
Dublin 434
Warsaw 355
Modena 318
Ho Chi Minh City 307
New York 297
The Dalles 291
Los Angeles 278
Hanoi 266
Dallas 264
San Diego 244
Izmir 219
Chicago 188
Princeton 186
Sofia 186
Lauterbourg 181
Eugene 174
Milan 169
Jakarta 158
Buffalo 143
Hefei 132
Shanghai 116
Moscow 114
Columbus 107
Dong Ket 103
São Paulo 92
Tokyo 84
Seoul 83
Falls Church 82
Munich 77
Frankfurt am Main 74
Orem 71
Boardman 70
Phoenix 69
Bremen 63
Da Nang 63
Fremont 63
Salt Lake City 63
Rome 56
Redwood City 55
Baghdad 53
Ottawa 53
Bologna 48
Atlanta 47
Guangzhou 46
Toronto 40
Redondo Beach 39
Mumbai 38
Brussels 36
Miano 36
San Giuliano Milanese 36
Brooklyn 35
Belo Horizonte 34
Chennai 32
Haiphong 32
Tampa 32
Des Moines 30
Naples 30
Poplar 30
Rio de Janeiro 30
Denver 29
Norwalk 29
Tashkent 29
Cairo 28
Montreal 26
Turku 25
Brasília 24
Mexico City 24
Miami 24
Florence 23
Nuremberg 23
Dhaka 22
Lawrence 22
Asyut 21
Düsseldorf 21
Falkenstein 21
Nanjing 21
Detroit 20
Johannesburg 20
Kilburn 20
Totale 33.201
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 630
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 588
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 455
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 445
GD2 expression in breast cancer. 427
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 427
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 425
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 403
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 397
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 375
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 366
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 363
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 362
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 356
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 356
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 354
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 353
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 351
The evolving role of microsatellite instability in colorectal cancer: A review 351
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 346
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 345
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 332
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 332
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 331
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 330
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 326
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
5-Fluorouracil pharmacogenomics: still rocking after all these years? 317
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 317
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 317
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 316
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 316
Transient sunitinib resistance in gastrointestinal stromal tumors. 314
Il trattamento di prima e seconda linea nel carcinoma gastrico 314
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 314
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 312
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 312
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 307
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 306
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 302
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 300
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 293
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 292
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 290
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 289
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 284
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 283
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 281
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 280
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 277
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 277
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 276
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 274
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 271
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 271
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 269
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 269
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 267
The Italian Rare Pancreatic Exocrine Cancer Initiative 267
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 265
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 263
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 261
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 260
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 260
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 258
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 257
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 253
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 253
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 252
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 251
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 250
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 249
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 248
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 247
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 246
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 245
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 245
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 244
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 242
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 241
Bone metastases- Pharmacological treatment 239
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 238
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 238
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 236
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 236
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 236
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 236
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 235
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 234
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 234
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 234
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 233
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 232
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. 231
BRAF-mutated colorectal cancer: Clinical and molecular insights 230
Totale 30.140
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.292 0 431 327 152 96 237 184 191 373 348 642 311
2022/20233.538 411 357 221 315 409 418 51 283 766 41 148 118
2023/20242.030 76 115 115 190 417 121 250 346 43 53 95 209
2024/20256.810 273 93 122 455 1.438 1.039 487 457 825 394 413 814
2025/202613.065 678 270 874 1.092 1.539 1.360 1.859 701 1.269 1.139 1.260 1.024
2026/2027564 530 34 0 0 0 0 0 0 0 0 0 0
Totale 46.369